Blau is a leading pharmaceutical industry in the institutional segment and a pioneer in biotechnology, with a proprietary portfolio of high-complexity medications focusing on relevant segments in the industry such as immunology, hematology, oncology, nephrology, specialties, and antibiotics, operating in various therapeutic classes.
It has a continental footprint, present in 7 countries – Brazil, Argentina, Colombia, Ecuador, Peru, Uruguay, and the United States, with a plasma collection operation – and a modern pharmaceutical industrial complex consisting of five industrial plants with state-of-the-art technology dedicated to the production of biological, biotechnological, oncological, antibiotic, injectable anesthetic medications, and biotechnological supplies.
Blau's portfolio consists of own-branded products – biological and synthetic – of high complexity, catering to the major therapeutic areas in the hospital products market, including infectology, oncology, hematology, nephrology, and specialties, with significant potential for consumption growth.
To create a neutral and completely anonymous environment, we entered a partnership with Contato Seguro, a third-party and entirely exempt organization.
The Reporting Channel is a place where you can send suggestions and reports of conduct that is unethical or inconsistent with our way of thinking and acting. Your information is protected.
Contato Seguro serves companies from various segments, in several Brazilian states and more than 37 countries, contributing to the transparency process and the maintenance of the ethical principles of each client.